Summary & Overview
HCPCS M1413: PD-L1 Positive Prior to First-Line Immune Checkpoint Inhibitor Therapy
HCPCS Level II code M1413 denotes documentation that a patient had a positive PD-L1 biomarker expression test result before starting first-line immune checkpoint inhibitor therapy. This designation matters nationally because PD-L1 status increasingly informs treatment selection, payer coverage decisions, and prior authorization criteria for immunotherapies in oncology. Clear coding for biomarker-driven treatment pathways supports appropriate clinical documentation and facilitates claims processing tied to targeted therapies.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how M1413 is used in clinical workflows and billing, typical sites of service where the code applies, and the relevance of PD-L1 positivity to treatment decisions. The publication outlines common billing considerations and benchmarks for documentation completeness.
This report provides clinical context on PD-L1 testing as a companion diagnostic for immune checkpoint inhibitors, summarizes payer coverage landscapes at a national level, and highlights areas where policy updates or payer requirements commonly affect use of the code. Data not available in the input are explicitly noted where applicable.
Billing Code Overview
HCPCS Level II code M1413 describes patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy. This code captures a clinical biomarker status used to document patient eligibility or selection for first-line immunotherapy based on PD-L1 expression.
Service type: Biomarker result documentation / Pre-treatment molecular testing assessment
Typical site of service: Oncology clinic, hospital outpatient department, or other settings where first-line immune checkpoint inhibitor therapy is initiated
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with newly diagnosed metastatic non–small cell lung cancer (adenocarcinoma) presents to a medical oncology clinic for treatment planning. Prior to initiating first-line immune checkpoint inhibitor therapy, the oncology team orders a programmed death-ligand 1 (PD-L1) immunohistochemistry assay on the diagnostic tumor biopsy specimen. The laboratory returns a positive PD-L1 biomarker expression result, reported as a tumor proportion score that meets the threshold for single-agent or chemoimmunotherapy selection. Documentation is placed in the chart indicating the positive pd-l1 result, the assay method, and date of the test. The oncology clinician cites the positive biomarker when authorizing initiation of a first-line immune checkpoint inhibitor regimen and records the medical necessity and treatment plan in the office visit note. Typical workflow steps include specimen collection/processing, pathology reporting of PD-L1 expression, multidisciplinary review (medical oncology and pathology), prior authorization submission if required, and administration of the selected immune checkpoint inhibitor in an outpatient infusion center or hospital outpatient department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than normally required (rarely applicable to reporting a biomarker result but may apply when extensive additional analysis or documentation is needed). |